
Vigil Neuroscience (VIGL) Stock Forecast & Price Target
Vigil Neuroscience (VIGL) Analyst Ratings
Bulls say
Vigil Neuroscience Inc. is positioned favorably due to its focus on developing therapeutics that target neurodegenerative diseases, specifically leveraging its VG-3927 drug, which exhibits a favorable safety and engagement profile supporting once-daily dosing. The company's ongoing studies have shown promising biomarker data, indicating a nearly 50% dose-dependent reduction in TREM2 levels in cerebrospinal fluid, which signals robust and sustained target engagement relevant for disease-modifying potential. As Vigil secures a comprehensive natural history package and integrates multiple biomarkers and imaging data into its studies, the resulting data set is expected to strengthen its case for regulatory approvals and drive future growth.
Bears say
Vigil Neuroscience has experienced a significant decline in its stock price following the ALEC TREM2 data readout, with shares dropping 26% and a reported net loss of $23.8 million, equating to a GAAP EPS of -$0.57 in 4Q24. The company's valuation outlook has also deteriorated, as indicated by an increase in the discount rate to 35%, leading to a target price reduction from $24 to $13, despite this target still being above current trading levels. The potential for commercial execution failures and the competitive landscape pose additional risks that could adversely affect the company’s performance and stock value.
This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.
Vigil Neuroscience (VIGL) Analyst Forecast & Price Prediction
Start investing in Vigil Neuroscience (VIGL)
Order type
Buy in
Order amount
Est. shares
0 shares